Latest:
Dr Kraft on VEGF Inhibitor–Induced Hypertension in RCC
Shawna Kraft, PharmD, BCOP, discusses the incidence and mitigation of VEGF inhibitor–induced hypertension in patients with renal cell carcinoma (RCC).
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
American Oncology Network
Latest:
American Oncology Network Celebrates Momentous Five-Year Anniversary of Closing the Cancer Care Gap
American Oncology Network, one of the fastest-growing community oncology networks in the United States, proudly celebrated its fifth anniversary, commemorating a half-decade of excellence in advancing community oncology and driving value-based care initiatives to close the cancer care gap.
Yago L. Nieto, MD, PhD
Latest:
Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple Myeloma
Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.
Selina M. Luger, MD, FRCPC
Latest:
Women in Oncology: Prioritization and Passionate Legacies
Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.
Nina D'Abreo, MD,
Latest:
Dr D'Abreo on Patient Consideration When Choosing Treatments in HER2+ Breast Cancer
Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.
Julie E. Chang, MD
Latest:
COVID-19 Pandemic Highlights Underrecognized Vulnerability of Patients With CLL
At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.